A life sciences research and development (R&D) cloud platform that includes no-code software and empowers scientists to automate experimentation and share information in a single, unified, environment by making collaboration and automation easier for scientists to leverage says it is helping to lower the accessibility and reproducibility barriers that occur in scientific research.
Synthace, the first life sciences software company to enable scientists to automate biology experimentation and insight sharing in a unified, global R&D environment today announced it raised $35 million in Series C funding to fuel commercial and go-to-market (GTM) growth as Synthace continues to reinvent the full value chain of life sciences R&D.
The company also plans to expand its senior leadership team in the US, with new vice presidents of marketing and sales joining the US-based CEO.
“Synthace’s R&D cloud platform is helping life scientists completely change the way they develop new cures and therapeutics to solve humanity’s most pressing problems,” said Guy Levy-Yurista, CEO of Synthace.
“But to maximize impact, we need to expand access and reach to customers across the globe—at scale. This investment serves as a strong vote of confidence from world-class investors in the biopharmaceutical and innovation technology industries. With their support, we’ll be able to better deploy human and financial capital to help transform scientific dreams into drugs and alternative food sources.”
“I envisaged an automated platform where our molecular biology and protein purification workflows proceeded end to end with sample tracking and barcoding throughout,” noted Tony Keeley, senior protein scientist at agtech Syngenta.
“Working closely with the Synthace team has enabled this to happen.”
